Abstract:sations. Alexithymic trait scores were characterized using established classification scores (scores 6 61). Statistical analyses were carried out in a 2-step logistic regression approach. All possible factors were entered simultaneously in a single block. All 2-way interactions between the possible risk factors were included. To select significant interactions, a backward elimination procedure with a threshold of p ! 0.20 was used. The final sample included 83 patients, with 73.5% males. The mean time to treatment was 176.75 8 239.65 min. In the analyses, 36 patients (43.4%) were allocated to the cases, 47 patients (56.6%) to the controls. Table 1 lists the frequencies of factors concerning the awareness of the disease and care-seeking behavior. None of the possible confounding factors taken into account differed between cases and controls in a statistically significant manner. However, the association between alexithymia (OR for cases 3.7, 95% CI 1.3–10.1) and contact with primary care prior to hospitalization (OR for cases 3.5, 95% CI 1.3–9.3) was statistically significant. No difference was found between cases and controls with regard to diagnosis of lifetime anxiety and depression. The multivariate analysis confirms the differences indicated by the univariate model but the two factors did not show any interaction, since the copresence of the two risk factors produced a cumulative risk without significant amplification (OR approx. 15.5, 95% CI 2.85–84.6; p ! 0.0001). The study shows that low emotional awareness, measured by alexithymia, and having had contact with primary care were associated with increased time to treatment in STEMI. No interaction was found between the two factors. An early study of Kenyon et al. [6] found evidence that the presence of alexithymia predicted a delay in seeking treatment in AMI. A study of O’Carroll et al. [7] , 10 years later, found some differences in alexithymia when comparing a group of patients with AMI who were prompt care seekers ( ! 4 h), and a group of late AMI care seekers ( 1 4 h) but these differences did not reach the threshold for statistical significance. Even so the results of such studies are partially in agreement with our data; the extension of their study sample might have biased the results since STEMI is the severest form of AMI and the only in which the delay in medical intervention is currently known to be of great danger [2] . On the other hand, ours is the first report in the literature exploring alexithymia as a potential risk factor for delay in seeking care in STEMI and also the first study to divide cases and controls with the delayed time known to be associated with a poor outcome (2 h) [2] . Sociodemographic and clinical variables did not independently appear to explain the delay. These results partially confirm the previous findings [8] . However, there appears to be some contradictory findings concerning consultation with a primary care The elapsed time between a person experiencing pain or discomfort due to an acute myocardial infarction (AMI) with ST segment elevation (STEMI) and his/her arrival at a hospital seeking care is crucial for survival. In fact, the degree of myocardial necrosis is related to the length of the ischemic episode [1] , and survival depends on the early provision of reperfusion techniques. If reperfusion occurs within 2 h, some preservation of myocardial function is achieved; after this period, life expectancy or survival decreases drastically [2] . The most important factor impacting on longer time to treatment is the patient’s decision to delay seeking care [1] . Thus, psychological variables such as alexithymia influencing the decision may be relevant. Unfortunately many of the findings with respect to psychosocial factors in delayed care seeking are still controversial [3] . We sought to explore psychological factors that might explain the delay in seeking care in STEMI with particular attention to alexithymia. Consecutive patients aged 18–85 years, admitted to a Cardiology Ward at Cagliari University Hospital, from April 2010 to June 2011, diagnosed with STEMI according to the European Society of Cardiology guidelines [2] were eligible for this study. The study sample was divided based on ‘time to treatment’, defined as the interval between the onset of symptoms and the first diagnostic ECG: controls = early care-seeking patients ( ! 2 h); cases = late care-seeking patients ( 1 2 h). A form was to be filled in to record sociodemographic data, health service utilization and risk factors [4] ; the study adopted the nonpatient version of the SCID-I-DSM-IV [4] and the Italian version of the 20-item Toronto Alexithymia Scale (TAS-20) [5] , a self-reporting checklist measuring the ability to identify and describe feelings and to distinguish between feelings and bodily senReceived: February 27, 2012 Accepted after revision: June 16, 2012 Published online: March 28, 2013

β-Amyloid Peptides Decrease Soluble Guanylyl Cyclase Expression in Astroglial Cells

Botulinum toxin in the treatment of blepharospasm and hemifacial spasm

Clinical Application of Botulinum Toxin for Hemifacial Spasm

Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm

EphA2/Ephrin-A1 Mediate Corneal Epithelial Cell Compartmentalization via ADAM10 Regulation of EGFR Signaling

Studies on the formation of hexamine from formaldehyde and ammonium salts in aqueous solution.

Alexithymia Is Associated with Delayed Treatment Seeking in Acute Myocardial Infarction

Positive effect of self-exercise following Botulinum toxin injection on the permanence of the recovery among the patients with HFS and BFS: A clinical trial

Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy

Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm

Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes

Resin hemoperfusion in acute digoxin intoxication.

[Botulinum toxin in ENT medicine]

Levator Labii Superioris Alaeque Nasi Targeted Botulinum Toxin Injection for Treatment of Perinasal Facial Discomfort and Snarling

MAM: more than just a housekeeper.

Use of botulinum toxin in the management of dystonia in Parkinson's disease

Correlation Between Blepharospasm and Psychological Diseases: the Anxiety, Depression and Sleep Disorder Study

Down‐regulation of miRNA‐204 by LMP‐1 enhances CDC42 activity and facilitates invasion of EBV‐associated nasopharyngeal carcinoma cells

Unilateral periocular spasm

Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm

Terrien's marginal degeneration associated with posterior polymorphous dystrophy.